Trial Profile
A randomized, double-blinded, single-center, placebo controlled, cross-over study to assess the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) on cardiac function in patients with chronic obstructive pulmonary disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms CLAIM
- Sponsors Novartis
- 14 Jan 2019 Results published in the American Journal of Respiratory and Critical Care Medicine
- 19 Sep 2018 Results assessing the impact of lung deflation on pulmonary microvascular perfusion, presented at the 28th Annual Congress of the European Respiratory Society
- 23 May 2018 Results (n=62) presented at the 114th International Conference of the American Thoracic Society.